Impact Factor 3.845 | CiteScore 3.92
More on impact ›

Original Research ARTICLE Provisionally accepted The full-text will be published soon. Notify me

Front. Pharmacol. | doi: 10.3389/fphar.2019.00990

Si-Miao-Yong-An Decoction protects against cardiac hypertrophy and dysfunction by inhibiting platelet aggregation and activation

Congping Su1,  Qing Wang1,  Huimin Zhang1,  Wenchao Jiao1,  Hui Luo1,  Lin Li1,  Xiangyang Chen2, Bin Liu2, Xue Yu1,  Sen Li3*, Wei Wang1* and  Shuzhen Guo4*
  • 1School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, China
  • 2School of Chinese Materia Medica, Beijing University of Chinese Medicines, China
  • 3School of Life Sciences, Beijing University of Chinese Medicine, China
  • 4Beijing University of Chinese Medicine, China

The aim of this study was to determine whether SMYAD could ameliorate pressure overload-induced heart hypertrophy and its mechanisms.
C57BL/6 mice were subjected to either sham or transverse aortic constriction (TAC) surgery to induce heart hypertrophy. SMYAD (14.85g/kg/d, po) or Captopril (16.5mg/kg/d, po) was administered to the mice for 4 weeks. Cardiac function was evaluated based on echocardiography. Histological and biochemical examination were also performed by HE staining. Protein expression of CD41, CD61, P-selectin were measured with western blotting and immunohistochemistry.
Four weeks after transverse aortic constriction, mice developed exaggerated cardiac hypertrophy and demonstrated a strong decrease in left ventricular ejection fraction (LVEF) compared with sham (29.9±9.3% versus 66.0±9.9%; P<0.001). Conversely, SMYAD improved cardiac dysfunction with a preserved LVEF (66.5±17.2%; P<0.001). The same changes were observed in left ventricular posterior wall, left ventricular volume and left ventricular internal diameter. The ratio of heart weight to body weight was also significantly increased 4 weeks after TAC, which could be rescued by SMYAD. Furthermore, western blot and immunohistochemistry indicated that the protein expressions of platelet aggregation marker (CD41, CD61) and platelet activation marker (P-selectin) were significantly higher compared to control. These pathological alterations in TAC-mice were significantly ameliorated or blocked by SMYAD administration.
Our results suggested that SMYAD exerted its effect by inhibiting platelet aggregation and activation as revealed by CD41/CD61/P-selectin up-regulation. Activation of the platelet might contribute to the therapeutic effects of SMYAD in failing heart.

Keywords: Si-miao-yong-an decoction, cardiac hypertrophy, Heart Failure, Platelet Activation, transverse aortic constriction

Received: 07 Apr 2019; Accepted: 05 Aug 2019.

Edited by:

Jianxun Liu, China Academy of Chinese Medical Sciences, China

Reviewed by:

Qiyang Shou, Zhejiang Chinese Medical University, China
Meiping Wu, Shanghai University of Traditional Chinese Medicine, China  

Copyright: © 2019 Su, Wang, Zhang, Jiao, Luo, Li, Chen, Liu, Yu, Li, Wang and Guo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence:
Prof. Sen Li, School of Life Sciences, Beijing University of Chinese Medicine, Beijing, 100029, China,
Prof. Wei Wang, School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China,
Prof. Shuzhen Guo, Beijing University of Chinese Medicine, Beijing, China,